

1 **Title:** Epidemiology of RSV-A and RSV-B in Adults and Children with Medically-Attended
2 Acute Respiratory Illness over Three Seasons

3

4 **Authors & Affiliations:** Katherine M. Begley¹, Aleda M. Leis¹, Joshua G. Petrie^{1*}, Rachel
5 Truscon¹, Emileigh Johnson¹, Erin McSpadden¹, Lois E Lamerato², Melissa Wei³, Arnold S.
6 Monto¹, Emily T. Martin¹

7 ¹Department of Epidemiology, University of Michigan School of Public Health

8 ²Department of Public Health Sciences, Henry Ford Health

9 ³Department of Medicine, University of California Los Angeles

10 *Current affiliation: Center for Clinical Epidemiology & Population Health, Marshfield Clinic
11 Research Institute, Marshfield, WI

12

13 **Corresponding Author:**

14 Emily T. Martin, PhD MPH

15 University of Michigan School of Public Health

16 1415 Washington Heights

17 Ann Arbor, Michigan 48109

18 Phone: 734-647-4723

19 Email: etmartin@umich.edu

20

21 **Word Count:** 2,956

22 **Abstract Length:** 222

23

24 **Footnotes:** Conflicts of Interest: ETM has received research funding from Merck related to the
25 submitted work. LL has received consulting fees from Janssen paid to institution.

26 **Funding Statement:** Supported in part by a research grant from the Investigator-Initiated
27 Studies Program of Merck Sharp & Dohme Corp. The opinions expressed in this paper are those
28 of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp.
29 The data was previously presented at ReSViNET 2021.

30 **Abstract**

31 Background: RSV is a frequent cause of respiratory illness less often diagnosed outside hospital
32 settings; thus, overall prevalence of RSV-associated illness is under-recognized. Information
33 about presence of RSV among those with chronic conditions is especially needed with recent
34 advances in vaccine development.

35 Methods: Participants prospectively enrolled in an ambulatory surveillance study of respiratory
36 illness (MFIVE) were tested by RT-PCR for RSV and influenza. Participant and illness
37 characteristics were collected by in-person survey and EMR review. Chronic conditions were
38 characterized by the Multimorbidity-weighted index (MWI). Viral factors, including subtype and
39 viral load, were compared between RSV-A and RSV-B. Multivariate logistic regression models
40 were used to compare participant and illness characteristics between those with RSV and those
41 with influenza. Comparisons were also made across RSV subtypes.

42 Results: Among 4,442 individuals enrolled in MFIVE from fall 2017 to spring 2020, 9.9%
43 (n=441) had RSV detected. RSV+ participants with increased viral load had increased odds of
44 illness lasting ≥ 7 days [OR_{adj}=2.39 (95% CI: 1.03-5.51) p-value=0.04]. Adults with RSV had
45 higher median MWI scores compared to influenza and RSV/influenza-negative (1.62, 0.40, 0.64,
46 respectively).

47 Conclusions: Our findings support the need for ongoing RSV surveillance, particularly in older
48 adults and those with multimorbidity. Our findings support a recognition of multimorbidity as a
49 significant contributor to RSV-associated MAARI among outpatient adults, with particularly
50 notable impacts among adults under 65.

51 **Keywords:** respiratory syncytial virus; child; adult; viral load; multimorbidity

52

53 **Introduction**

54 Respiratory Syncytial Virus (RSV) is one of the leading global causes of acute
55 respiratory illness (ARI) among children and is known to be a significant cause of ARI among
56 high-risk adults, particularly those with underlying cardiopulmonary conditions [1–5].
57 Assessments of multi-year patterns of RSV-A and RSV-B epidemiology in both children and
58 adults with medically attended acute respiratory illness (MAARI) are needed for the outpatient
59 setting to inform the need for and use of future RSV vaccines.

60 Older adults experience a higher incidence of RSV-associated MAARI as well as severe
61 RSV-associated illness outcomes, including hospitalization, when compared to younger adults
62 [6–9]. An individual’s health history – such as age and underlying chronic conditions, especially
63 among adults – and characteristics of the virus – including subtype and viral load – may
64 contribute to increased RSV severity. The prevalence of multimorbidity – the coexistence of
65 multiple underlying chronic conditions – increases significantly with age. As individuals with
66 multimorbidity are more likely to experience adverse health outcomes [10–14], multimorbidity
67 may also increase the risk of respiratory virus infection or the outcomes of medically-attended
68 acute respiratory illness.

69 The primary objective of this study was to describe characteristics and illness outcomes
70 among adults and children with MAARI at outpatient clinics located in southeast Michigan
71 between 2017 and 2020. To do so, we evaluated the relationship between quantitative viral load
72 and illness outcomes and whether viral subtype modified these associations and described the
73 impact of multimorbidity on RSV illness in adults.

74 **Methods**

75 *Source Population*

76 Data and specimens for this study were available from three respiratory virus seasons—2017/18,
77 2018/19, and 2019/20—of the Michigan Henry Ford Influenza Vaccine Effectiveness (MFIVE)
78 study. Data collection was ended on March 13, 2020 due to COVID-19 mitigation. MFIVE is an
79 ongoing, prospective, ambulatory-care study in southeast Michigan with coverage across 19
80 (2017/18), 23 (2018/19), and 22 (2019/20) outpatient clinics. MFIVE enrolls over 1,000 people
81 annually with MAARI for analysis of influenza vaccine effectiveness [15–18]. Patients six
82 months of age and older presenting with medically attended acute respiratory illness (MAARI)
83 meeting a standard case definition (lasting \leq seven days with a cough) and who have not taken
84 influenza antiviral treatment for their current illness were eligible for participation.

85

86 *Data collection*

87 Following informed consent, MFIVE research staff conducted an enrollment interview to collect
88 demographic and household characteristic data, information on their current illness and overall
89 health status, and vaccination status. Staff collected throat and nasal swab specimens and
90 delivered them to the Michigan Center for Respiratory Virus Research and Response for
91 processing and storage. Seven days post-enrollment, participants received an online follow-up
92 questionnaire to complete at home. Through this survey, participants self-reported illness
93 duration and recovery metrics, including subsequent care-seeking behavior. The University of
94 Michigan and Henry Ford Health Institutional Review Boards provided ethical approval for this
95 work.

96

97 *Illness Characteristics*

98 The number of symptoms reported—fever, sore throat, congestion—were operationalized
99 dichotomously for assessing symptom burden (low 0-1 symptoms vs. high 2-3 symptoms), using
100 any combination of symptoms reported. Length of illness was determined using self-reported
101 illness onset date recorded at enrollment and recovery date from the follow-up survey and then
102 dichotomized as extended illness (≥ 7 days) or not (< 7 days). Variables for subsequent seeking
103 of medical care or treatment were combined and dichotomized (sought subsequent treatment,
104 yes/no) and included visiting a doctor’s office, urgent care clinic, retail pharmacy clinic, or
105 emergency department/hospital.

106

107 *Clinical Data*

108 Electronic Health Record (EHR) data were abstracted to obtain ICD-10 diagnosis codes
109 indicating high-risk conditions up to one year prior to enrollment, and all ICD-10 codes recorded
110 by the healthcare provider seen at enrollment. Participant date of birth, sex and height
111 (centimeters) and weight (kilograms) closest to enrollment for calculating BMI (kg/m^2) were also
112 abstracted.

113

114 *Viral Characteristics*

115 Viral RNA was extracted with QiaAmp Viral RNA mini kits (Qiagen, Germany). RSV,
116 influenza, and other viral respiratory pathogens (Rhinovirus, Parainfluenza, Human
117 metapneumovirus, Seasonal coronaviruses, Bocavirus, Adenovirus, and Enterovirus) were
118 detected by RT-PCR using Fast Track Diagnostics real-time multiplex PCR respiratory panel
119 (Siemens Healthineer Company, Luxembourg). Sample viral subtype and quantitative viral load
120 were determined by Real-Time PCR (RT-PCR) on an ABI 7500 instrument (Thermo Fisher

121 Scientific), protocol described elsewhere [19,20]. All test plates included nuclease-free water as
122 a negative control as well as six RNA transcript standards, ranging from 1×10^4 – 1×10^9 copies
123 of viral RNA. Viral load was determined through comparing unknown samples to transcript
124 standards using curves generated by qPCR.

125

126 *Multimorbidity-weighted index (MWI)*

127 To determine adult multimorbidity status, the main exposure, we applied the
128 Multimorbidity Weighted Index (MWI), a validated, patient-centric measure of multimorbidity
129 adapted for ICD-10 compatibility [21,22]. The MWI measures the impact of underlying
130 conditions on patient physical functioning. Ninety-five conditions were represented in the MWI
131 across the following categories: cardiovascular, endocrine, gastrointestinal, hematologic,
132 immunologic, integumentary, musculoskeletal, nervous, oncologic, ophthalmologic, oral,
133 psychiatric, pulmonary, renal, and reproductive [21].

134 All ICD-10 diagnosis codes extracted from participant EHR were included to construct
135 individual MWI scores using available macros on SAS software version 9.4 (SAS Institute, Cary
136 NC). For the primary analysis we evaluated multimorbidity continuously and dichotomously (>0
137 versus 0 MWI), where indicated.

138

139 *Statistical Analysis*

140 Participants with RSV were compared to two groups: participants positive for influenza
141 and participants negative for both RSV and influenza. Overall descriptive statistics were
142 calculated for all eligible study participants.

143 For statistical analyses, data from all seasons were pooled to increase power, and study
144 year was included in regression models for pooled data. Age was categorized using
145 epidemiologically meaningful cut points: 0-4 years, 5-17 years, 18-49 years, 50-64 years, and \geq
146 65 years, respectively). Race (White, Black, and Other), education status (Less than High
147 School, Graduated High School/GED, Some College, Bachelor's Degree, and Advanced Degree)
148 and obesity (BMI \geq 30). Time between illness onset and specimen collection was categorized (0-
149 2 days and 3+ days). Viral load was log₁₀-transformed for analysis as a continuous variable as
150 well as dichotomized using median viral load as the cut point. Using median sample viral load as
151 a threshold, samples with a quantitative viral load $\geq 2.2 \times 10^4$ copies/mL (log₁₀-transformed \geq
152 4.3) were compared to samples with a quantitative viral load $< 2.2 \times 10^4$ copies/mL (log₁₀-
153 transformed < 4.3).

154 For viral characteristic analyses, all RSV-positive participants with subtype and viral load
155 data available were included. Pearson's *r* correlation coefficient was used to assess the
156 association between log viral load and viral subtype. The Mann-Whitney U Test was used to
157 detect differences in viral load (copies/mL) between RSV-A and RSV-B samples.

158 To test the association between quantitated viral load and RSV-associated illness
159 outcomes, both univariate and multivariable Firth logistic regression models were constructed,
160 and odds ratios reported. Multivariable models were adjusted for age, sex, race, season, and time
161 between illness onset and specimen collection. Firth-adjusted regression models were used to
162 account for potential bias from smaller outcome counts in stratified analyses [23]. We provide
163 overall and age-stratified estimates, where indicated, as well as estimates stratified by viral
164 subtype to assess effect modification. To test for effect modification more precisely, a statistical

165 interaction term between viral load and viral subtype was included in all overall illness outcome
166 models.

167 For multimorbidity analyses, only adults ICD codes were included. Participants under the
168 age of 18 were excluded from multimorbidity analyses as the MWI is not validated for use in
169 children. Descriptive statistics were calculated separately for adults included in multimorbidity
170 analyses. Firth-adjusted multivariate logistic regression models were used to assess the
171 association between multimorbidity and ARI outcomes, adjusting for age, sex, race, and season.
172 All statistical analyses were conducted on SAS software version 9.4 (SAS Institute, Cary NC).

173

174 **Results**

175 *Epidemiology*

176 From 2017-2020, 4,490 people were enrolled in MFIVE; 16 participants were excluded from this
177 analysis due to inconclusive RSV testing and 32 participants were excluded due to RSV-
178 influenza co-detection (Figure 1). Overall (n=4,442), 441 study-eligible cases of RSV, 1,341
179 cases of influenza, and 2,660 participants negative for both RSV and influenza were included
180 (Figure 2).

181 The annual proportion of RSV detection among participants under 18 years of age with
182 MAARI across 2017/18, 2018/19, and 2019/20 was 17.0%, 11.8%, and 10.4%, respectively.
183 Among children aged 0-4 years old across all study years (n=719), 23.8% (n=171) had RSV
184 detected, which was slightly higher than the proportion of children in that age group with
185 influenza detected (20.0%, n=144). The annual prevalence of symptomatic RSV among adults
186 with MAARI across included study years was 9.4%, 6.8%, and 6.9%, respectively. These
187 estimates were comparatively lower than the annual prevalence of symptomatic influenza among

188 adults (36.3%, 18.5%, and 31.4%, respectively) and children (32.6%, 34.7%, and 40.0%,
189 respectively) with MAARI in our study.

190 The median age of those with RSV detected was younger than those with influenza
191 detected as well as those who were negative for both RSV and influenza (Table 1). Over two-
192 thirds of adults with RSV detected had an MWI score above zero (68.6%, n=142). In contrast,
193 58% of adults with influenza detected or neither RSV nor influenza detected had an MWI score
194 above zero. Even with a significant presence of multimorbidity across all study participants,
195 92.6% (n=4,114) reported being in ‘Good Health’. Among adult participants (n=2,701), those
196 with RSV (1.2%, n=33) or influenza (7.2%, n=194) detected had children under the age of
197 twelve residing in their household, compared to 16% (n=433) of adults negative for RSV and
198 influenza.

199

200 *Illness Outcomes*

201 Over three-quarters of patients with influenza detected (78.5%, n=1,053) reported
202 experiencing a fever at their enrollment visit, compared to roughly half for participants with RSV
203 (54.2%, n=239) or neither (46.3%, n=1,231) detected. A sore throat was more often reported by
204 those with influenza (67.3%, n=902) or neither (68.0%, n=1,808) detected compared to those
205 with RSV detected (55.1%, n=243) (X^2 , p-value < 0.0001), and an overwhelming majority of all
206 participants reported congestion as a symptom (87.3%, n=3,878). Nearly half of participants with
207 influenza detected reported having all three symptoms (49.1%, n=658), and a majority of those
208 with RSV (51.2%, n=226) or neither (46.5%, n=1,236) detected reported the presence of two
209 symptoms (X^2 , p-value < 0.0001). Overall, 63.9% of participants completed the follow-up survey
210 after their illness visit (n=2,838). Nearly 40% of these participants with RSV detected reported a

211 length of illness equal to seven days or longer (Table 2). Of those who responded to the follow-
212 up survey, 11.6% of participants with RSV, 7.7% with influenza, and 8.8% with neither detected
213 reported seeking subsequent care (X^2 , p-value = 0.03).

214 *RSV Viral Characteristics*

215 Among RSV-positive samples with subtyping data available (86.4%, n=381), 62.2%
216 (n=237) were RSV-B and 37.8% (n=144) were RSV-A (Figure 1). Viral subtype was
217 undetermined for 13.6% (n=60) of RSV specimens, and quantitative viral load was undetermined
218 for 7.5% (n=28) of specimens and these were excluded from respective analyses. RSV-B was the
219 most common subtype detected across these three respiratory illness seasons (Figure 2). Among
220 samples with viral load determined (n=353), quantitated viral load ranged from 2.09×10^1 to
221 1.10×10^9 copies/mL and median viral load was 2.20×10^4 copies/mL (log₁₀-transformed = 4.3).
222 Log₁₀-transformed viral load was weakly but significantly correlated with viral subtype ($r =$
223 0.23, p-value < 0.0001), and RSV-B samples had significantly higher viral loads (copies/mL)
224 when compared to RSV-A samples (Mann-Whitney test, p-value < 0.0001).

225 After adjusting for age, gender, season, race, and time between illness onset and
226 specimen collection, the odds were 1.88 times higher that RSV-B samples had a high viral load
227 (defined as $\geq 2.20 \times 10^4$ copies/mL) when compared to RSV-A samples [OR_{adj} = 1.88 (95% CI:
228 1.14-3.11), p-value = 0.01] (Table 3). When stratified by adults and children, the effect size
229 became stronger in children (n=193) [OR_{adj} = 2.44 (95% CI: 1.25-4.77), p-value < 0.01], whereas
230 it was attenuated and no longer significant in adults (n=160) [OR_{adj} = 1.22 (95% CI: 0.56-2.65),
231 p-value = 0.61].

232 After adjusting for age, sex, race, season, viral subtype, and time between illness onset
233 and specimen collection, those with high viral load had significantly higher odds of experiencing

234 an extended length of illness when compared to those with a lower viral load (n=166) [OR_{adj} =
235 3.14 (95% CI: 1.25-7.93), p-value = 0.02] (Supplementary Table 2). After stratification by RSV
236 subtype and adjusting for age, sex, race, season, and time between illness onset and specimen
237 collection, participants with RSV-A detected (n=54) had a larger effect estimate [OR_{adj} = 4.88
238 (95% CI: 0.82-29.1), p-value = 0.08] compared to participants with RSV-B detected (n=112)
239 [OR_{adj} = 2.30 (95% CI: 0.75-7.06), p-value = 0.15]. However, an interaction term for viral load
240 and RSV subtype in the overall statistical model was not significant (p-value=0.61).

241

242 *Multimorbidity Analysis*

243 The relationship between ARI and multimorbidity was examined for adult enrollees
244 (n=2,681; Supplementary Table 1). For all three years, the most common condition categories
245 among adults were pulmonary (20.7%), endocrine (38.4%), and cardiovascular (15.9%). The top
246 three prevalent conditions detected across all study years were elevated cholesterol
247 hyperlipidemia, diabetes, and asthma. Calculated non-zero MWI scores for individual RSV-
248 positive adults ranged from 0.15-25.9, whereas scores ranged from 0.15-54.54 in influenza-
249 positive adults and 0.15-36.57 in the negative control group. The median MWI score of RSV-
250 positive adults in this sample higher than that in influenza-positive adults and RSV-negative /
251 influenza-negative adults (1.62, 0.40, 0.64, respectively) (Figure 3, Supplementary Table 3).
252 Across all groups, median MWI scores were similar for those who sought subsequent care and
253 those who did not. Adults with RSV had higher overall median MWI scores across various
254 illness outcomes, including reporting congestion or sore throat, two symptoms total, and
255 experiencing a length of illness more than seven days (Supplementary Table 3). After adjusting

256 for age, sex, season, and race, there were no statistically significant associations between
257 multimorbidity and illness outcomes for any infection group (Table 4).

258

259 **Discussion**

260 In this population presenting for outpatient care for symptomatic respiratory illness, we
261 identified a substantial prevalence of RSV among both children (13.4%) and adult (7.7%)
262 populations, respectively, with both RSV-A and RSV-B co-circulating through all three years of
263 the study. Nearly one-quarter of children aged 0-4 years old (23.8%) with MAARI during the
264 study had RSV detected. Similarly, Jackson et al. found the highest mean annual incidence of
265 medically attended RSV among children between the ages of one and four years old [7]. We
266 found viral load differed by subtype, and there was no difference in sample timing between
267 RSV-A and RSV-B specimens. Viral load was also associated with reported length of illness.

268 Studies of hospitalized infants predating the introduction of molecular methods, have
269 suggested that RSV-A was more likely to cause severe illness or necessitate intensive care when
270 compared to RSV-B [24–26]. In contrast, and in line with multiple early studies, Monto and
271 Ohmit found no differences in illness characteristics between the two subtypes in a community
272 setting [27–31]. More recent studies describing the relationship between RSV subtype, viral
273 load, and illness severity have focused primarily on hospitalized infant populations and report
274 varied results. In contrast to our findings, a study of hospitalized infants by Rodriguez-Fernandez
275 et al. found that RSV-A samples had significantly higher quantitative viral loads when compared
276 to RSV-B samples [32]. Walsh et al. assessed RSV illness severity in infants – measured via
277 hospitalization, ICU admission, and the need for ventilation – and concluded viral load did not
278 differ by illness severity [33].

279 As age increases so does the presence of chronic conditions, putting individuals at greater
280 risk of hospitalization or death due to RSV-associated illness. Specifically, diabetes and chronic
281 obstructive pulmonary disease have long been recognized as risk factors for severe respiratory
282 viral disease. The presence of these conditions has frequently been used to prioritize vaccination,
283 particularly in adults under 65. As vaccine development for RSV progresses, it is increasingly
284 important to recognize the presence of RSV in individuals with chronic disease, the total burden
285 of which is represented by multimorbidity. We have previously found that adults hospitalized
286 with RSV had significantly higher median Charlson Comorbidity Index scores (3 vs. 2, p-value <
287 0.001) when compared to those with influenza detected [3]. Although adults with RSV were
288 younger than adults with influenza in our ambulatory study population, we found that adults
289 seeking medical care for symptomatic RSV-associated illness had significantly higher median
290 multimorbidity scores when compared to adults seeking medical care for symptomatic ARI with
291 influenza or neither RSV nor influenza detected. This indicates that underlying multimorbidity,
292 and the functional impact of the multimorbidity, is important to consider when identifying adults
293 at risk for RSV-associated MAARI, and this population may benefit from priority vaccination
294 against RSV in the future.

295 The inclusion of influenza-positive and RSV-negative, influenza-negative participants
296 allowed us to make meaningful interpretations of RSV risk factors and severity. The MWI – as
297 opposed to Charlson Comorbidity Index or Elixhauser Method – provides a more meaningful
298 metric for assessing the impact of multimorbidity for this analysis because it accounts for the co-
299 occurrence of multiple conditions and is validated against outcomes other than mortality,
300 including physical functioning and cognitive status, which are more relevant to this ambulatory
301 care population. Additional strengths of this study include prospective screening and enrollment

302 of participants who met a pre-established MAARI case definition as well as the use of highly
303 sensitive and specific molecular testing for virus detection and RSV subtype and viral load
304 determination.

305 Our analysis underscores RSV as a substantial cause of MAARI among adults and
306 children in an ambulatory care setting and provides additional insight into the complex
307 relationships between viral characteristics and illness characteristics. Our findings reinforce that,
308 similarly to influenza, consistent differentiation of RSV subtype is warranted to improve RSV
309 surveillance and inform future vaccine development and implementation. Further, we provide
310 data supporting multimorbidity as a significant contributor to RSV-associated MAARI among
311 outpatient adults, with particularly notable impacts among adults under 65. Increasing efforts to
312 regularly include older adults and those with multimorbidity in the identification and
313 management of RSV-associated MAARI in the outpatient setting may reduce disease burden as
314 well as subsequent care utilization.

315

316 **References**

- 317 1. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory Syncytial Virus
318 Infection in Elderly and High-Risk Adults. *New England Journal of Medicine*. **2005**;
319 352(17):1749–1759.
- 320 2. Falsey AR, Formica MA, Hennessey PA, Criddle MM, Sullender WM, Walsh EE.
321 Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary
322 disease. *Am J Respir Crit Care Med*. **2006**; 173(6):639–643.
- 323 3. Malosh RE, Martin ET, Callear AP, et al. Respiratory syncytial virus hospitalization in
324 middle-aged and older adults. *J Clin Virol*. **2017**; 96:37–43.

- 325 4. Sundaram ME, Meece JK, Sifakis F, Gasser RA Jr, Belongia EA. Medically Attended
326 Respiratory Syncytial Virus Infections in Adults Aged ≥ 50 Years: Clinical Characteristics
327 and Outcomes. *Clinical Infectious Diseases*. **2014**; 58(3):342–349.
- 328 5. Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus
329 infection in elderly persons. *J Infect Dis*. **2004**; 189(2):233–238.
- 330 6. Belongia EA, King JP, Kieke BA, et al. Clinical Features, Severity, and Incidence of RSV
331 Illness During 12 Consecutive Seasons in a Community Cohort of Adults ≥ 60 Years Old.
332 *Open Forum Infect Dis*. **2018**; 5(12):ofy316.
- 333 7. Jackson ML, Scott E, Kuypers J, Nalla AK, Roychoudury P, Chu HY. Epidemiology of
334 Respiratory Syncytial Virus Across Five Influenza Seasons Among Adults and Children
335 One Year of Age and Older—Washington State, 2011/2012–2015/2016. *The Journal of*
336 *Infectious Diseases*. **2021**; 223(1):147–156.
- 337 8. McClure DL, Kieke BA, Sundaram ME, et al. Seasonal Incidence of Medically Attended
338 Respiratory Syncytial Virus Infection in a Community Cohort of Adults ≥ 50 Years Old.
339 *PLoS One*. **2014**; 9(7):e102586.
- 340 9. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations Associated With Influenza
341 and Respiratory Syncytial Virus in the United States, 1993–2008. *Clin Infect Dis*. **2012**;
342 54(10):1427–1436.
- 343 10. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of
344 multimorbidity and implications for health care, research, and medical education: a cross-
345 sectional study. *The Lancet*. Elsevier; **2012**; 380(9836):37–43.

- 346 11. Koroukian SM. Multimorbidity Redefined: Prospective Health Outcomes and the
347 Cumulative Effect of Co-Occurring Conditions. *Prev Chronic Dis* [Internet]. **2015** [cited
348 2021 Dec 9]; 12. Available from: https://www.cdc.gov/pcd/issues/2015/14_0478.htm
- 349 12. Lai FTT, Wong SYS, Yip BHK, et al. Multimorbidity in middle age predicts more
350 subsequent hospital admissions than in older age: A nine-year retrospective cohort study of
351 121,188 discharged in-patients. *European Journal of Internal Medicine*. Elsevier; **2019**;
352 61:103–111.
- 353 13. Salisbury C, Johnson L, Purdy S, Valderas JM, Montgomery AA. Epidemiology and impact
354 of multimorbidity in primary care: a retrospective cohort study. *Br J Gen Pract*. British
355 *Journal of General Practice*; **2011**; 61(582):e12–e21.
- 356 14. Wei MY, Kabeto MU, Galecki AT, Langa KM. Physical Functioning Decline and Mortality
357 in Older Adults With Multimorbidity: Joint Modeling of Longitudinal and Survival Data. *J*
358 *Gerontol A Biol Sci Med Sci*. **2019**; 74(2):226–232.
- 359 15. Chung JR, Rolfes MA, Flannery B, et al. Effects of Influenza Vaccination in the United
360 States During the 2018–2019 Influenza Season. *Clinical Infectious Diseases*. **2020**;
361 71(8):e368–e376.
- 362 16. Dawood FS. Interim Estimates of 2019–20 Seasonal Influenza Vaccine Effectiveness —
363 United States, February 2020. *MMWR Morb Mortal Wkly Rep* [Internet]. **2020** [cited 2021
364 Dec 29]; 69. Available from: <https://www.cdc.gov/mmwr/volumes/69/wr/mm6907a1.htm>

- 365 17. Flannery B, Chung JR, Belongia EA, et al. Interim Estimates of 2017–18 Seasonal
366 Influenza Vaccine Effectiveness — United States, February 2018. *MMWR Morb Mortal*
367 *Wkly Rep.* **2018**; 67(6):180–185.
- 368 18. Jackson ML, Chung JR, Jackson LA, et al. Influenza Vaccine Effectiveness in the United
369 States during the 2015-2016 Season. *N Engl J Med.* **2017**; 377(6):534–543.
- 370 19. Kuypers J, Wright N, Morrow R. Evaluation of quantitative and type-specific real-time RT-
371 PCR assays for detection of respiratory syncytial virus in respiratory specimens from
372 children. *Journal of Clinical Virology.* **2004**; 31(2):123–129.
- 373 20. Martin ET, Kuypers J, Heugel J, Englund JA. Clinical disease and viral load in children
374 infected with respiratory syncytial virus or human metapneumovirus. *Diagnostic*
375 *Microbiology and Infectious Disease.* **2008**; 62(4):382–388.
- 376 21. Wei MY, Kabeto MU, Langa KM, Mukamal KJ. Multimorbidity and Physical and
377 Cognitive Function: Performance of a New Multimorbidity-Weighted Index. *The Journals*
378 *of Gerontology: Series A.* **2018**; 73(2):225–232.
- 379 22. Wei MY, Mukamal KJ. Multimorbidity, Mortality, and Long-Term Physical Functioning in
380 3 Prospective Cohorts of Community-Dwelling Adults. *American Journal of Epidemiology.*
381 **2018**; 187(1):103–112.
- 382 23. Firth D. Bias reduction of maximum likelihood estimates. *Biometrika.* **1993**; 80(1):27–38.

- 383 24. Hall CB, Walsh EE, Schnabel KC, et al. Occurrence of groups A and B of respiratory
384 syncytial virus over 15 years: associated epidemiologic and clinical characteristics in
385 hospitalized and ambulatory children. *J Infect Dis.* **1990**; 162(6):1283–1290.
- 386 25. McConnochie KM, Hall CB, Walsh EE, Roghmann KJ. Variation in severity of respiratory
387 syncytial virus infections with subtype. *J Pediatr.* **1990**; 117(1 Pt 1):52–62.
- 388 26. Walsh EE, McConnochie KM, Long CE, Hall CB. Severity of respiratory syncytial virus
389 infection is related to virus strain. *J Infect Dis.* **1997**; 175(4):814–820.
- 390 27. Hendry RM, Talis AL, Godfrey E, Anderson LJ, Fernie BF, McIntosh K. Concurrent
391 circulation of antigenically distinct strains of respiratory syncytial virus during community
392 outbreaks. *J Infect Dis.* **1986**; 153(2):291–297.
- 393 28. McIntosh ED, De Silva LM, Oates RK. Clinical severity of respiratory syncytial virus
394 group A and B infection in Sydney, Australia. *Pediatr Infect Dis J.* **1993**; 12(10):815–819.
- 395 29. Monto AS, Ohmit S. Respiratory Syncytial Virus in a Community Population: Circulation
396 of Subgroups A and B since 1965. *The Journal of Infectious Diseases.* Oxford University
397 Press; **1990**; 161(4):781–783.
- 398 30. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on
399 Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients
400 hospitalized with respiratory syncytial viral lower respiratory tract infection. *J Pediatr.*
401 **1995**; 126(2):212–219.

- 402 31. Wilson E, Orvell C, Morrison B, Thomas E. Pediatric RSV Infection During Two Winter
403 Seasons in British Columbia: A Role for Subgroup Analysis in Young Children? Canadian
404 Journal of Infectious Diseases. Hindawi; **1990**; 1(4):112–116.
- 405 32. Rodriguez-Fernandez R, Tapia LI, Yang C-F, et al. Respiratory Syncytial Virus Genotypes,
406 Host Immune Profiles, and Disease Severity in Young Children Hospitalized With
407 Bronchiolitis. J Infect Dis. **2018**; 217(1):24–34.
- 408 33. Walsh EE, Wang L, Falsey AR, et al. Virus-Specific Antibody, Viral Load, and Disease
409 Severity in Respiratory Syncytial Virus Infection. The Journal of Infectious Diseases. **2018**;
410 218(2):208–217.

411 *Figure Titles*

412 *Figure 1 Analytic Flow Chart*

413 *Figure 2 MFIVE MAARI Epidemiologic Curve by Detected Virus Type (2017-2020)*

414 *Figure 3 Multimorbidity Violin Plot*

415

416

417

418

419

420

421

422

423

424 *Table 1 Characteristics of participants by infection detection status (2017-2020), n (row %)*

	RSV- positive (n=441)	Influenza-positive (n=1,341)	RSV-negative, influenza-negative (n=2,660)
Age, median (IQR)	14 (2-54)	23 (8-54)	37 (10-57)
Age Group			
0-4 years	171 (23.8)	144 (20.0)	404 (56.2)
5-17 years	63 (6.2)	466 (45.6)	493 (48.2)
18-49 years	69 (5.6)	332 (27.1)	823 (67.2)
50-64 years	78 (8.6)	260 (28.6)	571 (62.8)
≥ 65 years	60 (10.6)	139 (24.5)	369 (64.9)
Female	242 (9.1)	752 (28.3)	1,664 (62.6)
Race			
White	310 (10.3)	865 (28.8)	1,824 (60.8)
Black	59 (7.6)	246 (31.7)	471 (60.7)
Other	72 (10.8)	230 (34.5)	365 (54.7)
Education ^a			
< High School	14 (9.9)	42 (29.8)	85 (60.3)
High School/GED	62 (11.0)	145 (25.7)	358 (63.3)
Some college	127 (9.9)	382 (29.7)	776 (60.4)
Bachelor's degree	114 (8.7)	415 (31.5)	787 (59.8)
Advanced degree	121 (11.0)	352 (32.0)	627 (57.0)
Obesity ^b	95 (7.4)	341 (26.4)	854 (66.2)
Self-reported good health ^c	401 (9.8)	1,262 (30.7)	2,451 (59.5)
Smoking ^d			
Every day	13 (10.4)	27 (21.6)	85 (68.0)
Some days	2 (3.0)	14 (21.2)	50 (75.8)
Never	189 (7.6)	682 (27.4)	1,615 (65.0)
Season			
2017/18	192 (12.7)	525 (34.7)	795 (52.6)
2018/19	169 (8.7)	478 (24.5)	1,306 (66.8)
2019/20	80 (8.2)	338 (34.6)	559 (57.2)
Multimorbidity Weighted Index >0 ^e	142 (9.0)	423 (26.8)	1,015 (64.2)
Children (<12) in household ^f	17 (5.9)	86 (29.9)	185 (64.2)

^a Missing education status (n=35); If participant < 18, parent's education was used; ^b Missing BMI data (n=30); Obesity not assessed in participants < 18; ^c Missing good health status data (n=4); ^d Didn't know or refused (n=24); Smoking not assessed in participants < 18; ^e Adults missing data for calculating MWI (n=20); Excludes participants < 18; ^f Restricted to adults ≥ 18 years (n=2,701)

426 *Table 2 Illness characteristics by infection detection status (2017-2020), n (%)*

	RSV-positive (n=441)	Influenza- positive (n=1,341)	RSV-negative, influenza-negative (n=2,660)
Length of Illness (days) *			
0-2	2 (0.45)	10 (0.75)	24 (0.90)
3-6	40 (9.1)	170 (12.7)	251 (9.4)
7+	176 (39.9)	479 (35.7)	941 (35.4)
Self-reported symptoms			
Fever	239 (54.2)	1,053 (78.5)	1,231 (46.3)
Sore throat	243 (55.1)	902 (67.3)	1,808 (68.0)
Congestion	417 (94.6)	1,194 (89.0)	2,267 (85.2)
Self-reported number of symptoms +			
1	87 (19.7)	169 (12.6)	596 (22.4)
2	226 (51.2)	503 (37.5)	1,236 (46.5)
3	120 (27.2)	658 (49.1)	746 (28.0)
Sought subsequent care **			
Yes	51 (11.6)	103 (7.7)	233 (8.8)
No	249 (56.5)	722 (53.8)	1,407 (52.9)

* n = 2,349 participants missing length of illness data

+ excludes those who reported 0 symptoms (n=101)

** n = 1,677 participants missing sought subsequent care data

427

428

429 *Table 3 Logistic regression analysis of viral load among those with RSV-B vs. RSV-A infection,*
 430 *stratified by adults and children*

	Unadjusted OR (95% CI)	p-value*	Adjusted OR (95% CI)	p-value*
Overall (n=353) ^b				
Viral load (copies/mL)				
$\geq 2.20 \times 10^4$	1.71 (1.10-2.67)	0.02*	1.88 (1.14-3.11)	0.01*
18+ (n=160) ^c				
$\geq 2.20 \times 10^4$	1.26 (0.62-2.54)	0.53	1.22 (0.56-2.65)	0.61
<18 (n=193) ^c				
$\geq 2.20 \times 10^4$	2.48 (1.37-4.49)	0.003*	2.44 (1.25-4.77)	0.009*

^a Reference group for all models $< 2.20 \times 10^4$ copies/mL

^b Adjusted for age, sex, season, race, and time between illness onset and specimen collection

^c Adjusted for sex, season, race, and time between illness onset and specimen collection

* Statistically significant at $\alpha = 0.05$

431

432

433 *Table 4 Adjusted odds ratios of illness outcomes among adults with multimorbidity compared to*
 434 *adults without multimorbidity by infection status, OR_{adj} (95% CI) and Wald p-values, (n)*
 435 *observations overall and included in model^{a, b}*

	RSV-positive	p-value	Influenza- positive	p-value	RSV/FLU Negative	p-value
Overall ^c	(n=207)		(n=730)		(n=1,744)	
Extended illness [□]	(n=80)		(n=304)		(n=695)	
Yes	1.63 (0.31-8.54)	0.56	1.03 (0.55-1.95)	0.93	0.92 (0.58-1.47)	0.73
No. of reported symptoms	(n=207)		(n=730)		(n=1744)	
High (≥ 2)	0.91 (0.43-1.93)	0.80	1.36 (0.89-2.08)	0.16	1.11 (0.87-1.41)	0.40
Subsequent care [§]	(n=128)		(n=422)		(n=1032)	
Yes	0.91 (0.29-2.86)	0.88	1.07 (0.59-1.94)	0.82	1.44 (0.98-2.10)	0.06

^a Reference group for extended illness and sought subsequent care outcomes was ‘No’, reference group for number of reported symptoms was ‘Low (< 2)

^b Adjusted for age, sex, race, and season


^c One influenza-positive adult and 19 adults negative for both did not have data to calculate an MWI score

[□] length of illness data missing for n=1,049 negative, n=127 RSV-positive, and n=426 influenza-positive adults.

[§] sought subsequent care data missing for n=712 negative, n=79 RSV-positive, and n=308 influenza-positive adults.


436

437



Cases of MAARI Detected by Virus

virus RSV-negative/Influenza-negative Influenza RSV-B RSV-A RSV Subtype Undetermined



Violin Plot of Multimorbidity Weighted Index (MWI-ICD10) Scores Stratified by Age Group
Boxplot Comparison of MWI-ICD10 Scores

